Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology

Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology

Approximately 1%–2% of children with Down syndrome (DS) develop acute myeloid leukemia (AML) prior to age 5 years. AML in DS children (ML-DS) is characterized by the pathognomonic mutation in the gene encoding the essential hematopoietic transcription factor GATA1, resulting in N-terminally truncate...

Full description

Bibliographic Details
Main Authors: Sonali P. Barwe, Ishnoor Sidhu, E. Anders Kolb, Anilkumar Gopalakrishnapillai
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Molecular Therapy: Methods & Clinical Development
Subjects:
Down syndrome
iPSC
CRISPR/Cas9
leukemia
GATA1s
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050120301923

Internet

http://www.sciencedirect.com/science/article/pii/S2329050120301923

Similar Items